The pathologies of rare diseases are difficult to understand because of the small number of patients impacted. For these individuals, limited treatment options are available in clinical practice. However, we must keep challenging ourselves to develop therapeutic drugs for diseases in uncharted areas, even if we are uncertain whether we will succeed. Otherwise, we would be abandoning the possibility of treatment.
To deliver innovative pharmaceuticals for the treatment of rare diseases for which no effective therapy is available or for which existing treatments are not fully effective, Daiichi Sankyo continues to take on the challenge of offering hope to patients with rare diseases by taking advantage of our strengths in science and technology.

• The TNAP^*4 inhibitor DS-1211, which targets pseudoxanthoma elasticum, has been evaluated in phase 1 clinical trials in the United States.

* Tissue-nonspecific alkaline phosphatase

•